Evidence map›Paper›PMID 38392309›Full record

ArticleBiology2024

A New Non-Obese Steatohepatitis Mouse Model with Cardiac Dysfunction Induced by Addition of Ethanol to a High-Fat/High-Cholesterol Diet.

Seiji Shiraishi, Jinyao Liu, Yuki Saito, Yumiko Oba, Yuiko Nishihara, Satomichi Yoshimura

Open access · goldAbstract read
In one paragraph

Article in Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. MetALD: Clinical aspects, pathophysiology and treatment.JHEP reports : innovation in hepatology · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Seiji ShiraishiExploratory Research Department, EA Pharma Co., Ltd., Fujisawa-shi 251-8555, Kanagawa, Japan.
Jinyao LiuStudent Medical Academia Investigation Lab, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, Japan.
Yuki SaitoExploratory Research Department, EA Pharma Co., Ltd., Fujisawa-shi 251-8555, Kanagawa, Japan.
Yumiko ObaStudent Medical Academia Investigation Lab, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, Japan.
Yuiko NishiharaExploratory Research Department, EA Pharma Co., Ltd., Fujisawa-shi 251-8555, Kanagawa, Japan.
Satomichi YoshimuraStudent Medical Academia Investigation Lab, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Yamaguchi, Japan.ORCID 0009-0003-9712-3049
EA Pharma (Japan) · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-obese metabolic dysfunction-associated steatotic liver disease (MASLD) has been associated with cardiovascular-related mortality, leading to a higher mortality rate compared to the general population. However, few reports have examined cardiovascular events in non-obese MASLD mouse models. In this study we created a mouse model to mimic this condition. In this study involving seven-week-old C57BL/6J male mice, two dietary conditions were tested: a standard high-fat/high-cholesterol diet (STHD-01) and a combined diet of STHD-01 and ethanol. Over periods of 6 and 12 weeks, we analyzed the effects on liver and cardiac tissues using various staining techniques and PCR. Echocardiography and blood tests were also performed to assess cardiac function and liver damage. The results showed that mice on the ethanol-supplemented STHD-01 diet developed signs of steatohepatitis and cardiac dysfunction, along with increased sympathetic activity, as early as 6 weeks. At 12 weeks, more pronounced exacerbations accompanied with cardiac dilation, advanced liver fibrosis, and activated myocardial fibrosis with sympathetic activation were observed. This mouse model effectively replicated non-obese MASLD and cardiac dysfunction over a 12-week period using a combined diet of STHD-01 and ethanol. This dietary approach highlighted that both liver inflammation and fibrosis, as well as cardiac dysfunction, could be significantly worsened due to the activation of the sympathetic nervous system. Our results indicate that alcohol, even when completely metabolized on the day of drinking, exacerbates the progression of non-obese MASLD and cardiac dysfunction.

Indexed as

cardiac dysfunctionethanolnon-obese metabolic dysfunction-associated steatotic liver diseaseSTHD-01sympathetic activation

Identifiers

PMID38392309
PMCPMC10886349
OpenAlexW4391430275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.